ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ALLO Allogene Therapeutics Inc

4.39
-0.07 (-1.57%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,377,673
Bid Price 4.38
Ask Price 4.58
News -
Day High 4.575

Low
2.23

52 Week Range

High
6.89

Day Low 4.41
Company Name Stock Ticker Symbol Market Type
Allogene Therapeutics Inc ALLO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.07 -1.57% 4.39 17:44:41
Open Price Low Price High Price Close Price Prev Close
4.41 4.41 4.575 4.47 4.46
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,353 1,377,673 $ 4.48 $ 6,171,261 - 2.23 - 6.89
Last Trade Time Type Quantity Stock Price Currency
18:02:40 10 $ 4.39 USD

Allogene Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
752.46M 169.09M - 243k -332.63M -1.97 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Allogene Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALLO Message Board. Create One! See More Posts on ALLO Message Board See More Message Board Posts

Historical ALLO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.474.634.144.341,688,532-0.08-1.79%
1 Month5.245.7754.124.772,715,339-0.85-16.22%
3 Months3.355.7752.614.092,775,0181.0431.04%
6 Months3.405.7752.233.462,586,1480.9929.12%
1 Year4.996.892.234.172,425,186-0.60-12.02%
3 Years33.5936.002.239.421,924,963-29.20-86.93%
5 Years26.4155.002.2313.951,428,570-22.02-83.38%

Allogene Therapeutics Description

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Your Recent History

Delayed Upgrade Clock